A2A Founder & CEO Edward Painter was a panelist at BIO Investor forum panel entitled "Applying artificial intelligence to improve therapy development today"
Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of
A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery. LEARN MORE